Dual Prognostic Significance of P2RY12 in Antithrombotic-Treated STEMI – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Jiqing Li et al, published in Journal of Thrombosis and Haemostasis, adding:
“The dual role of P2RY12: Impact of polymorphism and expression on ischemic events and bleeding in patients with ST-segment elevation myocardial infarction receiving antithrombotic therapy.
In 1828 STEMI patients on ticagrelor, P2RY12 polymorphisms and expression levels showed opposing effects on ischemic and bleeding risks, revealing novel nonlinear relationships for refined cardiovascular risk stratification.”
Title: The dual role of P2RY12: impact of polymorphism and expression on ischemic events and bleeding in patients with ST-segment elevation myocardial infarction receiving antithrombotic therapy
Authors: Jiqing Li, Zheng Gong, Shikun Wang, Jianhua Gu, Shuo Wu, Jiaojiao Pang, Yuguo Chen
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 1, 2026, 15:20Sohail Khan: What Comes After IV Thrombolysis
-
Sep 1, 2026, 15:09Harish Chowdary Gorrepati: The HALT Paradox After TAV
-
Sep 1, 2026, 14:53Josef Kroupa: Landmark PRAGUE-26 Trial Advances Interventional PE Treatment
-
Sep 1, 2026, 14:34Marcin Kurzyna: New NEJM Trial Evaluates Catheter-Directed Thrombolysis in PE
-
Sep 1, 2026, 14:18Rafael Gomes: CoCAP Study Challenges Prolonged DAPT After CABG
-
Sep 1, 2026, 09:16Nicolas Gendron: Real-World Data on Danaparoid in Patients with Suspected HIT
-
Sep 1, 2026, 08:24Cristina Chang: The Importance of The New ET Treatments
-
Sep 1, 2026, 07:22Abdul Mannan: ASH 2026 Guidelines – New Treatment Approach for Adult ITP
-
Sep 1, 2026, 07:20Alejandro González Veliz: Silent Atherosclerosis Starts Earlier Than We Think